St. Bartholomew's Hospital
13
0
0
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
7.7%
1 terminated/withdrawn out of 13 trials
83.3%
-3.2% vs industry average
31%
4 trials in Phase 3/4
40%
2 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
iSITE: Investigation of Somatic Alterations in Tumours of the Eye
Role: collaborator
Acute Kidney Injury - Epidemiology in Intensive Care Unit Patients 2: an International Multicenter Cohort Study
Role: collaborator
PARADISE: Predicting AF After Cardiac Surgery
Role: collaborator
Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer
Role: collaborator
COVID-19: Healthcare Worker Bioresource: Immune Protection and Pathogenesis in SARS-CoV-2
Role: collaborator
Training-induced Increased Left Ventricular Trabeculation
Role: collaborator
Same-day Cardiac Surgery Cancellation
Role: lead
Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer
Role: lead
Cyproterone Acetate in Treating Patients With Newly Diagnosed Stage III or Stage IV Prostate Cancer
Role: lead
Early Diagnosis of Aspergillosis in Patients at High Risk of Fungal Infection Caused by Treatment for Hematologic Cancer or Other Disease
Role: lead
Dexamethasone, Aspirin, and Diethylstilbestrol in Treating Patients With Locally Advanced or Metastatic Prostate Cancer
Role: lead
A Bengali Dietary Salt Study to Control Blood Pressure
Role: collaborator
Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS)
Role: lead
All 13 trials loaded